Sign In
Buy BMY
$54.72
+0.260 (+0.477%)
At Close: Jun 03, 2026
Bristol-Myers Squibb (NYSE:BMY) Stake Lifted by Iowa State Bank
08:08pm, Friday, 19'th Nov 2021 Transcript Daily
Iowa State Bank increased its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 0.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 65,763 shares of the biopharmaceutical company’s stock after buying an additional 433 shares during the quarter. Iowa […]
Bristol Myers Squibb: 5 Reasons To Buy The Current Dip, And 1 Caveat
07:19pm, Friday, 19'th Nov 2021 Seeking Alpha
Bristol-Myers Squibb (BMY) Investor Presentation - Slideshow
07:09pm, Friday, 19'th Nov 2021 Seeking Alpha
Bristol Myers'' Mavacamten Added Via $13B Myokardia Buyout, Hit By FDA Delay
05:33pm, Friday, 19'th Nov 2021 Benzinga
Bristol Myers Squibb & Co (NYSE: BMY ) has announced that the FDA has extended the decision date for mavacamten. Bristol Myers announced that the date has slid from January 28, 2022 , to April 28, 2022. The details were slim, but the Company said the FDA notified them Thursday Full story available on Benzinga.com
Kinase Inhibitors Market Recent Trends, Future Industry Growth & Forecasts To 2027: Bristol-Myers Squibb, Boehringer Ingelheim
03:25pm, Friday, 19'th Nov 2021 OpenPR
The global Kinase Inhibitors market was valued at 5083.65 Million USD in 2020 and will grow with a CAGR of 4.6% from 2021 to 2027. Due to rigorous regulatory rules, an increase in clinical studies for the commercialization of kinase
Bristol Myers Squibb: 5 Reasons To Buy The Current Dip, And 1 Caveat
02:19pm, Friday, 19'th Nov 2021
Bristol Myers Squibb is the pharma with the share price that refuses to budge. Over the past five years, shares are up just 2%.
U.S. FDA extends review of Bristol Myers'' heart disease drug
12:42pm, Friday, 19'th Nov 2021 Reuters
The U.S. health regulator has extended the review of Bristol Myers Squibb''s oral heart disease drug candidate mavacamten, which the company acquired in its $13 billion buyout of MyoKardia last year.
Bristol Myers' Mavacamten Added Via $13B Myokardia Buyout, Hit By FDA Delay
12:33pm, Friday, 19'th Nov 2021
Bristol Myers Squibb & Co (NYSE: BMY) has announced that the FDA has extended the decision date for mavacamten. Bristol Myers announced that the date has slid from January 28, 2022, to April 28, 2
FDA extends action date for Bristol-Myers Squibb''s mavacamten by three months
12:31pm, Friday, 19'th Nov 2021 Seeking Alpha
Bristol Myers Squibb Announces New PDUFA Date for Mavacamten
11:59am, Friday, 19'th Nov 2021 Business Wire
Bristol Myers Squibb Announces New PDUFA Date for Mavacamten
2 Dividend Stocks to Buy Right Now
11:00am, Friday, 19'th Nov 2021
These two drugmakers have a solid track record.
Look to Big Pharma for Healthy Dividends
04:39pm, Thursday, 18'th Nov 2021
Of the top nine members of Big Pharma with high dividend yields, Eli Lilly and Co. ( LLY , Financial) brings up the rear at 1.32%. But that hardly tells the full story.
3 Ideal Dogs Delight Buffett's November Dividend Holdings
08:58am, Thursday, 18'th Nov 2021
3 Ideal Dogs Delight Buffett's November Dividend Holdings
Health Care Stocks Cheapest in 30 Years: 5 With Big Dividends to Buy Now
07:35am, Thursday, 18'th Nov 2021
For years, one of the most dependable sectors, especially for more conservative investors, was health care, which includes the top pharmaceutical and biotech stocks.
Bristol-Myers Squibb (NYSE:BMY) Stock Position Cut by Eidelman Virant Capital
09:28pm, Wednesday, 17'th Nov 2021 Transcript Daily
Eidelman Virant Capital trimmed its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 1.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 81,810 shares of the biopharmaceutical companys stock after selling 925 shares during the period. Bristol-Myers Squibb accounts for 1.9% of []
